MarketCap
Facebook
X
TelegramAnnual report 2022
added 03-29-2023
Chembio Diagnostics Interest Expense 2011-2026 | CEMI
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Chembio Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 2.94 K | - | 836 | - | 335 | 9.5 K | 18.6 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.6 K | 335 | 6.45 K |
Quarterly Interest Expense Chembio Diagnostics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.07 K | - | 3.85 K | 7.72 K | - | - | - | 1.31 K | - | - | 749 | - | - | - | - | - | - | - | - | - | 335 | - | 2.82 K | 2.32 K | 2.44 K | - | 4.87 K | 4.03 K | 4.44 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.72 K | 335 | 3.16 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 19.89 | 10.93 % | $ 211 M |  China |
 |
Agilent Technologies
A
|
81 M | $ 120.39 | 2.46 % | $ 36.6 B |  USA |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
CareDx, Inc
CDNA
|
524 K | $ 17.63 | 4.75 % | $ 939 M | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 1.38 | -4.83 % | $ 1.84 M | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 24.37 | 3.57 % | $ 677 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 179.31 | 0.54 % | $ 8.89 B | USA |
 |
Interpace Biosciences
IDXG
|
-252 K | $ 2.2 | - | $ 9.73 M | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 198.61 | 1.4 % | $ 142 B | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 130.32 | 2.65 % | $ 20.7 B | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 520.0 | 3.74 % | $ 15 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 16.02 | 4.71 % | $ 484 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 29.09 | 1.89 % | $ 20 B |  Niderland |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Guardant Health
GH
|
-10.5 M | $ 86.4 | 5.1 % | $ 10.8 B | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | Niderland |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.91 | 6.97 % | $ 455 M | USA |
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.88 | 1.05 % | $ 93.5 K | USA |
 |
Biomerica
BMRA
|
367 | $ 2.1 | 0.96 % | $ 4.82 M | USA |
 |
Senseonics Holdings
SENS
|
-23 K | $ 6.75 | 0.45 % | $ 282 M | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 113.06 | 2.44 % | $ 9.33 B |  Irlanda |
 |
NeoGenomics
NEO
|
296 K | $ 8.35 | 4.38 % | $ 1.07 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 268.87 | 1.78 % | $ 22.4 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 120.85 | 0.37 % | $ 5.65 B | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 9.61 | 5.14 % | $ 2.08 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 82.74 | 1.31 % | $ 5.58 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 194.16 | 0.65 % | $ 21.6 B | USA |
 |
Natera
NTRA
|
9.32 M | $ 214.64 | 6.31 % | $ 21.1 B | USA |
 |
ENDRA Life Sciences
NDRA
|
460 K | $ 4.96 | -4.43 % | $ 3.9 M | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 17.04 | 1.34 % | $ 381 M | USA |
 |
Organovo Holdings
ONVO
|
6 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
7.56 K | - | -16.95 % | $ 1.54 M | USA |